Skip to main navigation

>> Site Menu

  • Our Company
  • Our Science
    • ABCD Platform
    • Scientific Presentations
  • Focus Areas
    • Wet Age Related Macular Degeneration
    • Diabetic Eye Disease
    • Retinal Vein Occlusion
    • Macular Edema Secondary to Inflammation (MESI)
  • Our Pipeline
    • Tarcocimab Tedromer
    • KSI-501
    • KSI-101
  • Our Culture
    • Join the Team
  • INVESTORS & MEDIA
    • Overview
    • Press Releases
    • Events and Presentations
    • Stock Information
    • Analyst Coverage
    • SEC Filings
    • Corporate Governance
    • ESG Report
    • Investor Resources
Kodiak Sciences

>> Site Menu

  • Our Company
  • Our Science
    • ABCD Platform
    • Scientific Presentations
  • Focus Areas
    • Wet Age Related Macular Degeneration
    • Diabetic Eye Disease
    • Retinal Vein Occlusion
    • Macular Edema Secondary to Inflammation (MESI)
  • Our Pipeline
    • Tarcocimab Tedromer
    • KSI-501
    • KSI-101
  • Our Culture
    • Join the Team
  • INVESTORS & MEDIA
    • Overview
    • Press Releases
    • Events and Presentations
    • Stock Information
    • Analyst Coverage
    • SEC Filings
    • Corporate Governance
    • ESG Report
    • Investor Resources

News Releases

> News - Sub Nav

  • Press Releases

News Releases

March 31, 2026
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Additional Formats
PDF Version
March 26, 2026
Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham
Additional Formats
PDF Version
February 4, 2026
Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026
Additional Formats
PDF Version
January 7, 2026
Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
Additional Formats
PDF Version
 
 
 
Disclaimer

Some of the statements on this site are forward-looking. Such statements are inherently subject to known as well as unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of Kodiak Sciences to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements speak only as of the date they are posted to this website (unless an earlier date is indicated). Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country.

KODIAK SCIENCES INC.

1250 Page Mill Rd
Palo Alto, CA 94304
United States of America

Kodiak Sciences GMBH
Dammstrasse 19
6300 ZUG
Switzerland

info@kodiak.com

Kodiak Sciences Valais GMBH
Rottenstrasse 5
3930 VISP
Switzerland

LinkedIn Twitter
Copyright © 2026 Kodiak Sciences Inc.